DENVER, Colo., 14 June, 2024 (247marketnews.com) – (Nasdaq:AIMD) are discussed in this article.
Ainos Inc. has made significant advancements in the clinical trials of its revolutionary “Ainos Flora” volatile organic compound (VOC) point-of-care testing (POCT) device, which is powered by AI technology. In a series of rigorous clinical trials conducted at prestigious medical centers, the Ainos Flora device has successfully completed 75 clinical cases, demonstrating promising outcomes that lay a solid foundation for the next-generation Ainos Flora.
The clinical trials have confirmed the effectiveness of the AI algorithm model, showcasing improved recognition accuracy by incorporating real-world data into the Ainos AI model. Leveraging advanced pre-processing data and environmental correction algorithms has standardized data, overcoming individual and environmental variances. Moreover, enhancements in software and hardware designs have optimized the performance of the Ainos Flora, minimizing operational environment interferences.
Looking forward, Ainos is leveraging NVIDIA CUDA, a parallel computing platform, to develop the next version of the Ainos Flora device, expanding its test portfolio to include viral infection detection for decentralized healthcare applications in home testing settings. Scheduled for completion by the end of the third quarter, the updated Ainos Flora model aims to facilitate easy and precise test result retrieval without the need for medical expertise, aligning with the growing trend towards at-home testing solutions. Clinical trials are slated to commence in the fourth quarter.
Chun-Hsien (Eddy) Tsai, the Chairman of the Board, President, and CEO of Ainos, emphasized the pivotal role of Ainos Flora in addressing the demand for telehealth-friendly, rapid, and convenient multi-use test solutions for vaginal health and STI screening. With the global STI testing market forecasted to reach US$256 billion by 2028, Ainos strategically employs CUDA technology to expedite the development process.
Ainos’ commitment to fusing advanced deep learning algorithms with medical devices underscores its dedication to innovation in AI and medical technology. With a robust patent portfolio, the Company leads the way in AI Nose technology, seamlessly integrating AI deep learning with digital nose sensors to introduce a new era of rapid diagnostic tools for enhanced disease diagnosis and health monitoring. Honored with the 2021 iF Medicine/Health Design Award, the renowned Ainos Flora device exemplifies the Company’s mission to provide fast, confidential, and user-friendly testing experiences for individuals.
Ainos remains at the forefront of driving advancements in AI-enabled medical devices, telehealth services, and cloud applications to meet the rising demand for home healthcare solutions. By pioneering AI Nose-powered POCT solutions like Ainos Flora, the Company aims to revolutionize healthcare, making medical diagnostics more accessible and user-friendly for all. Visit https://www.ainos.com to learn more about Ainos, Inc. and its innovative healthcare solutions, and stay updated on the latest developments by following Ainos on social media platforms.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 Market News, Inc Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com